Following FDA IND clearance for neuropathic pain, the Company is preparing to initiate its U.S. Phase 2a trial in Q4 2025 ...

With approval to proceed, the Phase II trial (NCT06092034) of RP-A501 for Danon disease restarts under an optimized dosing ...

An overview of how recent funding reductions are reshaping clinical trial operations, from site sustainability and patient ...

Degrees Pharmaceuticals has entered into a clinical study agreement with the Icahn School of Medicine at Mount Sinai in the ...

Alpha1H shows benefit in non-muscle invasive bladder cancer, shrinking tumors and boosting the immune system with manageable ...

Akeso enrolls first patient in pivotal phase III trial of cadonilimab for perioperative treatment of resectable gastric cancer: Hong Kong Friday, August 22, 2025, 18:00 Hrs [IST] ...

Patient visits are now complete in the final cohort of Phase 1b trial, consisting of Parkinson’s disease patients receiving 300 mg doses of HER-096 or placebo twice weekly over a four-week ...

Historically, more than half of patients with GM2 gangliosidosis need to be fed via IV between 13 and 18 months of age. In ...

Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the ...

New research from Dana-Farber Cancer Institute shows that a new class of drug results in cell death in cancers, such as small ...

Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for difficult-to-treat cancers, today announced a Nature publication ...